Daniel J Lewis,Madeleine Duvic
Daniel J Lewis
Cutaneous T-cell lymphoma (CTCL) is characterized by the accumulation of neoplastic CD4+ T lymphocytes in the skin. Given the lack of curative treatments for CTCL, there is a significant need for new, superior therapies. Forodesine is a tra...
Brigette B Y Ma,Edwin P Hui,Anthony T C Chan
Brigette B Y Ma
Nasopharyngeal carcinoma (NPC) is endemic to Southern China and Asia and is etiologically associated with the Epstein Barr virus (EBV). Whole exome and genome sequencing (WES, WGS) studies of NPC have reported several actionable therapeutic...
Sheng-Min Wang,Changsu Han,Soo-Jung Lee et al.
Sheng-Min Wang et al.
Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms ...
Investigational Janus kinase inhibitors in development for myelofibrosis [0.03%]
在研的用于治疗骨髓纤维化的janus激酶抑制剂调查报告
Prithviraj Bose,Abdallah Abou Zahr,Srdan Verstovsek
Prithviraj Bose
Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the on...
Investigational and experimental GnRH analogs and associated neurotransmitters [0.03%]
研究中的促性腺激素释放激素类似物及其相关神经递质
Zeev Blumenfeld
Zeev Blumenfeld
The GnRH agonistic analogs enable for desensitizing the hypothalamo-pituitary-gonadal axis in malignant and benign conditions where minimizing the production of sex hormones, or blocking ovulation is necessary. The possible indications are ...
Matteo Ferrando,Diego Bagnasco,Fulvio Braido et al.
Matteo Ferrando et al.
Smooth muscle cell contraction in the airways is the principal therapeutic target in asthmatic subjects and its insufficient treatment is often a cause of uncontrolled disease. For this reason, research has focused on targeting smooth muscl...
Marie Robert,Jean-Sébastien Frenel,Carole Gourmelon et al.
Marie Robert et al.
Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to fam...
Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia [0.03%]
杜韋利西布：用于治疗慢性淋巴细胞白血病的磷脂酰肌醇-3激酶δ/γ抑制剂
Hima V Vangapandu,Nitin Jain,Varsha Gandhi
Hima V Vangapandu
Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease...
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer [0.03%]
研究药物靶向成纤维细胞生长因子受体治疗非小细胞肺癌
Erika Rijavec,Carlo Genova,Giulia Barletta et al.
Erika Rijavec et al.
Fibroblast growth factor receptor (FGFR) due to its central role in regulating cell survival, is a promising target for cancer therapeutics. Dysregulation of the FGFR pathway has been observed in several malignancies, including non-small ce...
Gilad Itchaki,Jennifer R Brown
Gilad Itchaki
Lenalidomide is an immunomodulatory drug (IMiD) with a unique mode of action (MOA) that may vary across disease-type. It is currently approved in multiple myeloma (MM), myelodysplastic syndrome (MDS) and mantle cell lymphoma (MCL), yet is a...